Puma Biotechnology Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Puma Biotechnology heeft een totaal eigen vermogen van $71.1M en een totale schuld van $78.1M, wat de schuld-eigenvermogensverhouding op 109.8% brengt. De totale activa en totale passiva bedragen respectievelijk $220.7M en $149.6M. De EBIT Puma Biotechnology is $33.0M waardoor de rentedekking 3.7 is. Het heeft contanten en kortetermijnbeleggingen van $96.7M.
Belangrijke informatie
109.8%
Verhouding schuld/eigen vermogen
US$78.08m
Schuld
| Rente dekkingsratio | 3.7x |
| Contant | US$96.73m |
| Aandelen | US$71.09m |
| Totaal verplichtingen | US$149.63m |
| Totaal activa | US$220.72m |
Recente financiële gezondheidsupdates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Recent updates
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $156.8M ) PBYI } overtreffen de korte termijn passiva ( $110.4M ).
Langlopende schulden: De kortetermijnactiva PBYI ( $156.8M ) overtreffen de langetermijnschulden ( $39.2M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: PBYI heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van PBYI is de afgelopen 5 jaar gedaald van 548.2% naar 109.8%.
Schuldendekking: De schuld van PBYI wordt goed gedekt door de operationele kasstroom ( 43.2% ).
Rentedekking: De rentebetalingen op de schuld van PBYI worden goed gedekt door EBIT ( 3.7 x dekking).